The réseau de recherche sur le cancer: Favoring a multi-disciplinary approach;Le réseau de recherche sur le cancer: Promotion d'une approche multidisciplinaire

Bulletin du Cancer

Volumn 93, Issue 9, 2006, Pages 831-834

  Mes Masson, Anne Marie ^a   Champoux, Louise ^a   Hébert, Josée ^b   Batist, Gerald ^c   Lespérance, Bernard ^d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Cancer; Clinical research; Fundamental research; Qu bec

Indexed keywords

CANADA; CANCER; CANCER RESEARCH; FACTUAL DATABASE; HEALTH SERVICE; INFORMATION DISSEMINATION; REVIEW; ARTICLE; FINANCIAL MANAGEMENT; HEALTH CARE FACILITY; HUMAN; LEUKEMIA; NEOPLASM; ONCOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PATHOLOGY; RESEARCH; RESOURCE ALLOCATION; TRANSPLANTATION;

ACADEMIES AND INSTITUTES; HUMANS; INFORMATION DISSEMINATION; LEUKEMIA; MEDICAL ONCOLOGY; NEOPLASMS; QUEBEC; RESEARCH; RESEARCH SUPPORT; RESOURCE ALLOCATION; TISSUE AND ORGAN PROCUREMENT; TISSUE BANKS;

EID: 33749048567     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Tonin P, Mes-Masson AM, Futreal A, Morgan K, Mahon M, Foulkes WD, et al. Recurrent BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998; 63: 1341-51.
2. Martin NL, Saba-El-Leil MK, Sadekova S, Meloche S, Sauvageau G. EN2 is a candidate oncogene in human breast cancer. Oncogene 2005; 24: 6890-901.
3. Gagné JP, Gagné P, Hunter HM, Bonicalzi ME, Lemay JF, Kelly I, et al. Proteome profiling of human epithelial ovarian cancer cell line TOV112D. Mol Cell Biochem 2005; 275: 25-55.
4. Quellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C, et al. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005; 24: 4672-87.
5. L'Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, et al. Gene expression profiling of paired tumor samples obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 2006 (in press).
6. Bachvarov D, L'Esperance L, Popa I, Bachvarova M, Plante M, Têtu B. Gene expression patterns of chemoresistant and chemosensitive ovarian serous adenocarcinomas with possible prognostic value in response to initial chemotherapy. Int J Oncol 2006; 29: 5-24.
7. Le Page C, Ouellet V, Hudson T, Filali-Mouhim A, Provencher D, et al. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum based markers in epithelial ovarian cancer. Int J Cancer 2006; 118: 1750-8.
8. Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Provencher D, Sanchez L, et al. Tissue array validation of microarrays candidates identifies new molecular markers that correlated with tumor grade and outcomes in serous epithelial ovarian cancer. Int J Cancer 2006; 119: 599-607.
9. Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 2006; 100: 389-96.
10. Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2006; 100: 83-8.
11. Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson A-M, et al. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutarion, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Med Genet 2006; 15: 23.
12. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423: 255-60.
13. Bijl J, Sauvageau M, Thompson A, Sauvageau G. High incidence of pro-viral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia. Genes Dev 2005; 19: 224-33.
14. Mamo A, Krosl J, Kroon E, Bijl J, Thompson A, Mayotte N, et al. Molecular dissection of Meis1 reveals 2 domains required for leukemia induction and a key role for Hoxa gene activation. Blood 2006; 108: 622-9.
15. Hazourli S, Chagnon P, Sauvageau M, Fetni R, Busque L, Hébert J. Over-expression of PRDM16 in the presence and absence of the RUNX1/PRDM16 fusion gene in myeloid leukemias. Gene Chrom Cancer 2006 (in press).